The Administrative Core of the Mayo Alzheimer's Disease Research Center will be responsible for the overall management of the Center. It will provide fiscal management, scientific direction, accountability, and communication with the National Alzheimer Coordinating Center and with other Alzheimer's Disease Centers. The ADRC will continue to pursue the scientific themes of the previous grant cycle, focusing on early detection of AD, particularly in the mild cognitive impairment (MCI) stage, and also focusing on non-AD dementias. The center will strive to expand AD research within the entire institution and will promote AD and non-AD dementia research nationally and internationally. The Core will oversee the pilot project program. The Core will have an Internal Steering Committee headed by the Center Director, and this Committee will oversee the scientific, personnel and fiscal issues of the Center. The Committee will also make the final judgment with regard to the awarding of pilot projects. The Core will continue with its ExternalAdvisory Committee, and this group will meet on an annual basis, alternating between Rochester, MN, and Jacksonville, FL. The Administrative Core will oversee the interactions among the cores and projects and will also integrate activities between Rochester, MN, and Jacksonville, FL. The Center will continue to provide relevant data to the National Alzheimer's Coordinating Center and will be compliant with the Uniform Data Set requirements. The Center Director and the staff will be responsible for compliance with the training requirements for key personnel as outlined by the Mayo Foundation, and all activities will be HIPAA compliant. The Director will communicate with the National Institute on Aging and provide annual progress reports.
(Seeinstructions): The Administrative Core of the ADRC oversees the overall function of the Center. The Core coordinates the activities of the two sites and integrates the activities of the cores and the projects to accomplish the scientific goals of the Center.
| Kang, Silvia S; Ebbert, Mark T W; Baker, Kelsey E et al. (2018) Microglial translational profiling reveals a convergent APOE pathway from aging, amyloid, and tau. J Exp Med 215:2235-2245 |
| Pakhomov, Serguei V S; Eberly, Lynn E; Knopman, David S (2018) Recurrent perseverations on semantic verbal fluency tasks as an early marker of cognitive impairment. J Clin Exp Neuropsychol 40:832-840 |
| Gallagher, Damien; Kiss, Alex; Lanctot, Krista et al. (2018) Depression and Risk of Alzheimer Dementia: A Longitudinal Analysis to Determine Predictors of Increased Risk among Older Adults with Depression. Am J Geriatr Psychiatry 26:819-827 |
| Sakae, Nobutaka; Bieniek, Kevin F; Zhang, Yong-Jie et al. (2018) Poly-GR dipeptide repeat polymers correlate with neurodegeneration and Clinicopathological subtypes in C9ORF72-related brain disease. Acta Neuropathol Commun 6:63 |
| Haaksma, Miriam L; Calderón-Larrañaga, Amaia; Olde Rikkert, Marcel G M et al. (2018) Cognitive and functional progression in Alzheimer disease: A prediction model of latent classes. Int J Geriatr Psychiatry 33:1057-1064 |
| Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872 |
| Jung, Youngsin; Jordan 3rd, Lennon G; Lowe, Val J et al. (2018) Clinicopathological and 123I-FP-CIT SPECT correlations in patients with dementia. Ann Clin Transl Neurol 5:376-381 |
| Jack Jr, Clifford R; Wiste, Heather J; Schwarz, Christopher G et al. (2018) Longitudinal tau PET in ageing and Alzheimer's disease. Brain 141:1517-1528 |
| Kidana, Kiwami; Tatebe, Takuya; Ito, Kaori et al. (2018) Loss of kallikrein-related peptidase 7 exacerbates amyloid pathology in Alzheimer's disease model mice. EMBO Mol Med 10: |
| Townley, Ryan A; Botha, Hugo; Graff-Radford, Jonathan et al. (2018) 18F-FDG PET-CT pattern in idiopathic normal pressure hydrocephalus. Neuroimage Clin 18:897-902 |
Showing the most recent 10 out of 1014 publications
